Genetically engineered hypoimmunogenic cell therapy
Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …
transplantation into immunocompetent patients. Genetic modification has emerged as a …
Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia
R Chiesa, C Georgiadis, F Syed, H Zhan… - … England Journal of …, 2023 - Mass Medical Soc
Background Cytidine deamination that is guided by clustered regularly interspaced short
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …
Genome editing in engineered T cells for cancer immunotherapy
C Bonini, AG Chapuis, M Hudecek, S Guedan… - Human Gene …, 2023 - liebertpub.com
Advanced gene transfer technologies and profound immunological insights have enabled
substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent …
substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent …
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
V Moradi, E Khodabandehloo, M Alidadi… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
CAR-T cell therapy has shown remarkable promise in treating B-cell malignancies, which
has sparked optimism about its potential to treat other types of cancer as well. Nevertheless …
has sparked optimism about its potential to treat other types of cancer as well. Nevertheless …
Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T‐cells for the treatment of Hyper IgM1
D Canarutto, C Asperti, V Vavassori, S Porcellini… - The EMBO …, 2023 - embopress.org
Hyper IgM1 is an X‐linked combined immunodeficiency caused by CD40LG mutations,
potentially treatable with CD4+ T‐cell gene editing with Cas9 and a “one‐size‐fits‐most” …
potentially treatable with CD4+ T‐cell gene editing with Cas9 and a “one‐size‐fits‐most” …
Allogeneic CAR T Cell Therapy for Cancer
BJ Sasu, EJ Lauron, T Schulz… - Annual Review of …, 2023 - annualreviews.org
Autologous chimeric antigen receptor (CAR) T cell therapy, produced from the patient's own
T cells, has changed the treatment landscape for hematologic malignancies but has some …
T cells, has changed the treatment landscape for hematologic malignancies but has some …
Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells
D Cappabianca, J Li, Y Zheng, C Tran… - … in Bioengineering and …, 2024 - frontiersin.org
Efficient engineering of T cells to express exogenous tumor-targeting receptors such as
chimeric antigen receptors (CARs) or T-cell receptors (TCRs) is a key requirement of …
chimeric antigen receptors (CARs) or T-cell receptors (TCRs) is a key requirement of …
[HTML][HTML] Cellular Therapies for Multiple Myeloma: Engineering Hope
S Vera-Cruz, M Jornet Culubret, V Konetzki, M Alb… - Cancers, 2024 - mdpi.com
Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease
course as well as intra-and inter-patient heterogeneity. Cellular immunotherapies, especially …
course as well as intra-and inter-patient heterogeneity. Cellular immunotherapies, especially …
[HTML][HTML] Genome editing approaches for universal chimeric antigen receptor T cells
Autologous chimeric antigen receptor (CAR) T cell therapy has revolutionised the
management of certain B-cell malignancies. However, as bespoke therapies, challenges …
management of certain B-cell malignancies. However, as bespoke therapies, challenges …